Mainstay Medical (MSTY.PA, MSTY FP)
Mainstay Medical is a specialist medical device company focused on commercialising ReActiv8, an innovative therapy for chronic lower back pain. The company obtained European approval for the device in 2016 and currently generates sales in Germany and Ireland with plans to expand into other regional markets. Mainstay expects to file an application with the FDA for US approval in mid-2019 with a decision expected in late 2020. The market opportunity for ReActiv8 is very material with an estimated c.2m patient candidates for ReActiv8 across the US and EU markets.
|Rica Universal S.A||7.9|
|Fountain Healthcare Partners||7.0|